NDA 016455 · Almirall
Cordran
Flurandrenolide · Topical · Corticosteroid
Last checked: Nov 19, 2026Latest source record: Jan 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1969
Jul 29, 1969
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
333
152 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 1969 Original approval · Type 3 - New Dosage Form
1 products under this application
- CORDRAN · FLURANDRENOLIDE 0.004MG/SQ CM · TAPE, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Flurandrenolide" as an intervention, any sponsor and status, largest first.
- Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit SitesPivotal-lookingCompleted
University Hospital Birmingham NHS Foundation TrustAcademic, hospital or other
NCT01996930 · 32 participants · Start Dec 2013 · Primary completion Mar 2017
Drug: Haelan tape (steroid impregnated tape); Silver Nitrate · For: Peritoneal Dialysis; Continuous Ambulatory Peritoneal Dialysis; End Stage Renal Failure and 1 more
Sites: Birmingham, United Kingdom; Exeter, United Kingdom; Hull, United Kingdom · 8 sites in all
- Haelan and Nutrition in Cancer PatientsTerminated
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00558558 · 6 participants · Start Oct 2007 · Primary completion Aug 2009
Drug: Haelan · For: Anorexia; Weight Loss; Cachexia
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus31
- drug ineffective30
- headache20
- nausea20
- rash19
- fatigue18
- pain18
- diarrhoea16
- psoriasis16
- depression14
- dyspnoea14
- pain in extremity14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 9 |
| 2014 | 11 |
| 2015 | 24 |
| 2016 | 20 |
| 2017 | 31 |
| 2018 | 22 |
| 2019 | 31 |
| 2020 | 24 |
| 2021 | 18 |
| 2022 | 22 |
| 2023 | 27 |
| 2024 | 20 |
| 2025 | 22 |
| 2026 | 27 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cordran (Flurandrenolide)
2024 spending
$3.4M
Beneficiaries
1,781
3,293 claims
Per beneficiary
$1,910
$796.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,082,695 |
| 2021 | $3,887,544 |
| 2022 | $3,549,294 |
| 2023 | $3,438,698 |
| 2024 | $3,401,214 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis.
Krueger GG, O'Reilly MA, Weidner M, et al. · J Am Acad Dermatol 1998 · Clinical Trial, Comparative Study
- New cream vehicle for flurandrenolide.
Jones EL, Crumley AF, Cornell RC · Cutis 1978 · Clinical Trial, Comparative Study
- Flurandrenolone (Cordran) tape and carbohydrate metabolizing enzymes. Use in the epidermis of people with psoriasis.
Halprin KM, Fukui K, Ohkawara A · Arch Dermatol 1969 · Clinical Trial, Controlled Clinical Trial
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.